Loading
STEAP1 is a protein on the surface of most prostate cancer cells, now the address for a T-cell engager in phase 3.
Six-transmembrane epithelial antigen of the prostate 1 is expressed in most prostate cancers including PSMA-low and neuroendocrine-like disease, with limited normal expression. Xaluritamig (STEAP1×CD3 XmAb 2+1) produced PSA50 in ~half of heavily pretreated mCRPC patients at target doses in phase 1 and is in two phase 3 trials (XALute post-taxane; XALience with abiraterone chemo-naive). Also an ADC target historically (vandortuzumab vedotin, discontinued).
In plain words · STEAP1 is a protein on the surface of most prostate cancer cells, now the address for a T-cell engager in phase 3.
Backbone ribbon from PDB 8UCD. RCSB PDB 8UCD. The ribbon widens where the chain is folded into a regular pattern and narrows where it is a loose loop.
STEAP1 is a protein on the surface of most prostate cancer cells, now the address for a T-cell engager in phase 3.
STEAP1 is a metalloreductase at cell junctions, upregulated by androgen receptor signalling; its expression is partly independent of PSMA, making it complementary.
1 product aims at STEAP1: bispecific antibodies. Because it sits on the outside of the cell, it can be reached from the bloodstream: antibodies flag the cell, ADCs deliver a toxin, radioligands deliver radiation, and CAR-T or bispecifics bring a T cell.
Tumour-associated overexpression: 1 cell-killing or cell-finding medicine (Xaluritamig) aim at the antigen, which HPA finds with no normal tissue stained high; the medicine relies on the tumour carrying more of it than the normal tissue it shares it with. HPA STEAP1: RNA tissue enhanced (prostate 79 nTPM); no normal tissue stained high; highest cancer staining lung cancer (1 of 11 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Prostate cancer); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 5 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas STEAP1 tissue; Human Protein Atlas STEAP1 pathology; Open Targets ENSG00000164647 associations
First described 1999. Earliest sequence paper UniProt cites for the protein: Hubert R.S. et al, Proc. Natl. Acad. Sci. U.S.A, 1999, "STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors". Source.
STEAP1 is a metalloreductase at cell junctions, upregulated by androgen receptor signalling; its expression is partly independent of PSMA, making it complementary.
RNA: tissue enhanced (prostate 79 nTPM), detected in many normal tissues.
No normal tissue stained high.
RNA cancer enriched: Prostate Adenocarcinoma 188 pTPM.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Xaluritamig is Amgen's T-cell engager for prostate cancer, now in two phase 3 trials, aiming to do for prostate cancer what tarlatamab did for small-cell lung cancer.
Query for this target: (TITLE:"STEAP1" OR ABSTRACT:"STEAP1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about STEAP1, not a curated reading list.
Shares Prostate cancer and the tag t-cell-engager-target.
Shares Xaluritamig and the tag t-cell-engager-target.
Shares Prostate cancer and the tag t-cell-engager-target.
Shares Xaluritamig, Prostate cancer.
Shares XALute, Prostate cancer.
Shares Xaluritamig, Prostate cancer.
Shares Owen N. Witte, Prostate cancer.